Candidate Compounds Covid19

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(37 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
{{pnc}}
+
{{gohome}}
 +
{{ft|P}}
 +
  '''CHERRYPICKING STUDIES IS NOT SCIENCE
 +
{{qt|Reviews on covid drug development}}
  
current items will be put into the subsections.
 
  
*[[reviews on covid drug development]]
+
*'''[[scouting ideas]]'''
*[[scouting ideas]]
+
  
*[[Patients on biologicals]]
+
*'''[[PHA Biologicals]]'''
*[[HMGB1, RAGE]]
+
*[[pre-Interleukin 6]]
+
*[[post-Interleukin 6]]
+
*[[pre-TNFalpha]]
+
*[[post-TNFalpha]]
+
*[[pre-Interleukin 17]]
+
*[[post-Interleukin 17]]
+
*[[pre-Interleukin 1]]
+
*[[post-Interleukin 1]]
+
*[[Inflammasome]] ''colchicine''
+
*[[Methotrexate]]
+
*[[other anti-inflammatory]]
+
*[[NK-kappaB]]
+
*[[STAT 3]]
+
*[[JAK Janus Kinase]]
+
*[[Corticosteroids]]
+
*[[Cytokine absorbers]]
+
*[[Target Complement system]]
+
*[[Target Extracellular traps]]
+
*[[TGF beta]]
+
*[[Anticoagulant in covid19]]
+
*[[Antioxidants]]
+
*[[Stem cells]]
+
*[[MDSC cells]]
+
*[[Interferons]]
+
  
 +
*'''[[PHA conventional pharmacology]]'''
  
*[[other single compounds]]
+
*'''[[PHA retargeted compounds]]'''
*[[Retargeted single compounds]]
+
*[[Hydroxychloroquine]]
+
*
+
*[[Target ACE2, Spike protein]]
+
*[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
+
*[[other antiviral compounds]]
+
*[[AV Remdesivir]]
+
*[[AV Lopinavir]]
+
*[[AV Ivermectin]]
+
*[[AV Arabidol]]
+
*[[AV Favipiravir]]
+
  
 +
*'''[[PHA antivirals by mechanism]]'''
  
 +
*'''[[PHA pharmacophore by screened target]]'''
  
*[[Vitamin D]]
+
*'''[[PHA ImmunoNutrients]]
*[[Anorganic nutrients Magnesium]]
+
*[[Anorganic nutrients Selenium]]
+
*[[Anorganic nutrients Zinc]]
+
*[[Nutrition, general]]
+
*[[Exercise, Vibration]]
+
  
 +
*'''[[PHA compl altern natural]]'''
  
*[[Traditional Chinese Medicine]]
+
*'''[[PHA within indications compounds]]'''
*[[Natural compounds]]
+
  
*[[Statins]]
+
*'''[[PHA Serum products]]'''
*[[Antidiabetic compounds, any]]
+
*[[RSP - On RAS drugs]]
+
  
*[[Reconvalescent blood products, Passive vaccine]]  
+
*'''[[PHA Vaccination]]'''
*[[Plasmapheresis]]
+
 
 +
PHA related options:
  
*[[Immunodeviation]] e.g. by adjuvants or other vaccinations
 
 
*[[Radiation therapy]]
 
*[[Radiation therapy]]
 
*[[Phototherapy]]
 
*[[Phototherapy]]
*[[Active vaccine]]  
+
*[[Electric fields]]
 
+
*[[Treatment other concepts]]
===008===
+
{{tp|p=32458400|t=2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.|pdf=|usr=008}}
+
 
+
{{tp|p=32401611|t=2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.|pdf=|usr=008}}
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32413736|t=2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.|pdf=|usr=008}}
+
 
+
 
+
 
+
{{tp|p=32450201|t=2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.|pdf=|usr=008}}
+
{{tp|p=32522674|t=2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32534188|t=2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32534094|t=2020. Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir(R)).|pdf=|usr=008}}
+
 
+
{{tp|p=32435920|t=2020. Lithium's antiviral effects: a potential drug for CoViD-19 disease?|pdf=|usr=008}}
+
{{tp|p=32382873|t=2020. Covid-19 and drug therapy, what we learned.|pdf=|usr=008}}
+
{{tp|p=32460369|t=2020. Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence.|pdf=|usr=008}}
+
{{tp|p=32412158|t=2020. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.|pdf=|usr=008}}
+
{{tp|p=32531935|t=2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.|pdf=|usr=008}}
+
 
+
{{tp|p=32470602|t=2020. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.|pdf=|usr=008}}
+
 
+
{{tp|p=32425638|t=2020. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.|pdf=|usr=008}}
+
{{tp|p=32522597|t=2020. Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients.|pdf=|usr=008}}
+
{{tp|p=32502659|t=2020. Potential role of statins in COVID-19.|pdf=|usr=008}}
+
{{tp|p=32521619|t=2020. Redox-Modulating Agents in the Treatment of Viral Infections.|pdf=|usr=008}}
+
{{tp|p=32461554|t=2020. Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32327922|t=2020. The 4 D's of Pellagra and Progress.|pdf=|usr=008}}
+
{{tp|p=32447429|t=2020. Trials and tribulations: so many potential treatments, so few answers.|pdf=|usr=008}}
+
{{tp|p=32483523|t=2020. Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.|pdf=|usr=008}}
+
{{tp|p=32426222|t=2020. The Ethics of COVID-19 Clinical Trials: New Considerations in a Controversial Area.|pdf=|usr=008}}
+
 
+
{{tp|p=32488835|t=2020. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.|pdf=|usr=008}}
+
 
+
{{tp|p=32458206|t=2020. Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?|pdf=|usr=008}}
+
{{tp|p=32411575|t=2020. Malnutrition Care during the COVID-19 Pandemic: Considerations for Registered Dietitian Nutritionists Evidence Analysis Center.|pdf=|usr=008}}
+
{{tp|p=32479759|t=2020. Successful use of methylprednisolone for treating severe COVID-19.|pdf=|usr=008}}
+
{{tp|p=32470486|t=2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.|pdf=|usr=008}}
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32527713|t=2020. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.|pdf=|usr=008}}
+
{{tp|p=32397940|t=2020. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors.|pdf=|usr=008}}
+
 
+
{{tp|p=32396773|t=2020. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.|pdf=|usr=008}}
+
 
+
{{tp|p=32396769|t=2020. Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach.|pdf=|usr=008}}
+
{{tp|p=32394467|t=2020. A global treatments for coronaviruses including COVID-19.|pdf=|usr=008}}
+
 
+
{{tp|p=32526460|t=2020. A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis.|pdf=|usr=008}}
+
 
+
{{tp|p=32517353|t=2020. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.|pdf=|usr=008}}
+
{{tp|p=32489508|t=2020. Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?|pdf=|usr=008}}
+
{{tp|p=32425662|t=2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.|pdf=|usr=008}}
+
 
+
{{tp|p=32384202|t=2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.|pdf=|usr=008}}
+
 
+
{{tp|p=32388906|t=2020. Do novel drugs for diabetes help in COVID-19? Another brick in the wall?|pdf=|usr=008}}
+
 
+
{{tp|p=32495299|t=2020. COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?|pdf=|usr=008}}
+
 
+
{{tp|p=32398164|t=2020. Drug repurposing against COVID-19: focus on anticancer agents.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32509284|t=2020. The need to implement non-industry COVID-19 clinical trials in non-high-income countries.|pdf=|usr=008}}
+
{{tp|p=32395245|t=2020. Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19.|pdf=|usr=008}}
+
{{tp|p=32360293|t=2020. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?|pdf=|usr=008}}
+
 
+
 
+
 
+
{{tp|p=32422152|t=2020. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects.|pdf=|usr=008}}
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32533263|t=2020. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.|pdf=|usr=008}}
+
{{tp|p=32405780|t=2020. Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.|pdf=|usr=008}}
+
 
+
{{tp|p=32383582|t=2020. When the Others Become Us: A Chemist's Perspective of the COVID-19 Outbreak in Italy.|pdf=|usr=008}}
+
{{tp|p=32432466|t=2020. Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19.|pdf=|usr=008}}
+
{{tp|p=32402186|t=2020. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.|pdf=|usr=008}}
+
{{tp|p=32428392|t=2020. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.|pdf=|usr=008}}
+
{{tp|p=32478500|t=2020. COVID-19 and Other Pandemics: How Might They Be Prevented?|pdf=|usr=008}}
+
{{tp|p=32519842|t=2020. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.|pdf=|usr=008}}
+
{{tp|p=32469114|t=2020. An update on ACE2 amplification and its therapeutic potential.|pdf=|usr=008}}
+
 
+
{{tp|p=32350686|t=2020. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.|pdf=|usr=008}}
+
{{tp|p=32454090|t=2020. The preventive strategy for pandemics in the elderly is to collect in advance samples & data to counteract chronic inflammation (inflammaging).|pdf=|usr=008}}
+
{{tp|p=32534451|t=2020. Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?|pdf=|usr=008}}
+
{{tp|p=32489694|t=2020. Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?|pdf=|usr=008}}
+
{{tp|p=32489692|t=2020. Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.|pdf=|usr=008}}
+
 
+
{{tp|p=32516203|t=2020. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate.|pdf=|usr=008}}
+
{{tp|p=32406904|t=2020. Clinical trials: management of investigational products during the coronavirus (COVID-19) pandemic.|pdf=|usr=008}}
+
 
+
{{tp|p=32479920|t=2020. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32310688|t=2020. Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity.|pdf=|usr=008}}
+
{{tp|p=32315803|t=2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.|pdf=|usr=008}}
+
{{tp|p=32519895|t=2020. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?|pdf=|usr=008}}
+
{{tp|p=32519894|t=2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.|pdf=|usr=008}}
+
{{tp|p=32519892|t=2020. Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.|pdf=|usr=008}}
+
{{tp|p=32297590|t=2020. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.|pdf=|usr=008}}
+
{{tp|p=32499129|t=2020. Immunotherapies for COVID-19: Restoring the immunity could be the priority.|pdf=|usr=008}}
+
 
+
{{tp|p=32505720|t=2020. Positive Outcome in a COVID-19 patient with Common Variable Immunodeficiency after IVIG.|pdf=|usr=008}}
+
{{tp|p=32534022|t=2020. COVID-19 and allergen immunotherapy: theoretical benefits invite to adjustments in practice recommendations.|pdf=|usr=008}}
+
{{tp|p=32534944|t=2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.|pdf=|usr=008}}
+
 
+
{{tp|p=32405693|t=2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?|pdf=|usr=008}}
+
 
+
{{tp|p=32436029|t=2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32489437|t=2020. Clinical trials for coronavirus disease 2019: What is being evaluated and what is not.|pdf=|usr=008}}
+
{{tp|p=32513797|t=2020. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle.|pdf=|usr=008}}
+
{{tp|p=32440665|t=2020. Cross-Protection Induced by Encephalitis Vaccines against COVID-19 Might be a Reason for Relatively Lower Mortality Rate in Some Countries.|pdf=|usr=008}}
+
 
+
{{tp|p=32493626|t=2020. S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32345532|t=2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.|pdf=|usr=008}}
+
{{tp|p=32399097|t=2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.|pdf=|usr=008}}
+
{{tp|p=32399096|t=2020. State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2.|pdf=|usr=008}}
+
{{tp|p=32399095|t=2020. State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2.|pdf=|usr=008}}
+
{{tp|p=32399094|t=2020. Statins and the COVID-19 main protease: in silico evidence on direct interaction.|pdf=|usr=008}}
+
{{tp|p=32399093|t=2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.|pdf=|usr=008}}
+
{{tp|p=32514689|t=2020. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.|pdf=|usr=008}}
+
 
+
{{tp|p=32446195|t=2020. Interactions of recommended COVID-19 drugs with commonly used psychotropics.|pdf=|usr=008}}
+
 
+
{{tp|p=32399655|t=2020. Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series.|pdf=|usr=008}}
+
{{tp|p=32470547|t=2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.|pdf=|usr=008}}
+
{{tp|p=32440566|t=2020. Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19.|pdf=|usr=008}}
+
 
+
{{tp|p=32458149|t=2020. Can Zn Be a Critical Element in COVID-19 Treatment?|pdf=|usr=008}}
+
{{tp|p=32532623|t=2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.|pdf=|usr=008}}
+
{{tp|p=32426388|t=2020. Computation screening of narcissoside a glycosyloxyflavone for potential novel coronavirus 2019 (COVID-19) inhibitor.|pdf=|usr=008}}
+
{{tp|p=32426387|t=2020. Artificial intelligence approach fighting COVID-19 with repurposing drugs.|pdf=|usr=008}}
+
{{tp|p=32534226|t=2020. Monoclonal antibody as a potential anti-COVID-19.|pdf=|usr=008}}
+
{{tp|p=32410772|t=2020. Emerging pharmacotherapies for COVID-19.|pdf=|usr=008}}
+
 
+
{{tp|p=32519753|t=2020. The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter.|pdf=|usr=008}}
+
 
+
{{tp|p=32383371|t=2020. Perspectives of Immune Therapy in Coronavirus Disease 2019.|pdf=|usr=008}}
+
{{tp|p=32508168|t=2020. Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review.|pdf=|usr=008}}
+
{{tp|p=32401215|t=2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.|pdf=|usr=008}}
+
 
+
{{tp|p=32410266|t=2020. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32391920|t=2020. Consider TLR5 for new therapeutic development against COVID-19.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32422320|t=2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.|pdf=|usr=008}}
+
{{tp|p=32454981|t=2020. Current regulatory approaches for accessing potential COVID-19 therapies.|pdf=|usr=008}}
+
{{tp|p=32468385|t=2020. Musings on the current state of COVID-19 modeling and reporting.|pdf=|usr=008}}
+
{{tp|p=32435882|t=2020. Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2.|pdf=|usr=008}}
+
 
+
{{tp|p=32406687|t=2020. In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease.|pdf=|usr=008}}
+
 
+
{{tp|p=32452670|t=2020. Immunity-Boosting Spices and the Novel Coronavirus.|pdf=|usr=008}}
+
{{tp|p=32525650|t=2020. Targeting SARS-CoV-2: Novel Source of Antiviral Compound(s) against COVID-19?|pdf=|usr=008}}
+
{{tp|p=32534130|t=2020. EPO in Patients With COVID-19: More Than an Erythropoietic Hormone.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32525715|t=2020. Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions.|pdf=|usr=008}}
+
{{tp|p=32396382|t=2020. Myth Busters: Dietary Supplements and COVID-19.|pdf=|usr=008}}
+
{{tp|p=32523147|t=2020. Anotaciones breves sobre el sindrome de liberacion de citocinas y el bloqueo terapeutico de la interleucina-6 en SARS-CoV-2/COVID-19.|pdf=|usr=008}}
+
{{tp|p=32523144|t=2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.|pdf=|usr=008}}
+
{{tp|p=32518135|t=2020. Paediatric treatment trials for COVID-19 are an ethical imperative.|pdf=|usr=008}}
+
{{tp|p=32522067|t=2020. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.|pdf=|usr=008}}
+
{{tp|p=32521191|t=2020. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?|pdf=|usr=008}}
+
{{tp|p=32515023|t=2020. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32533795|t=2020. Further aspects of doxycycline therapy in COVID-19.|pdf=|usr=008}}
+
{{tp|p=32533990|t=2020. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?|pdf=|usr=008}}
+
{{tp|p=32529218|t=2020. Statin therapy in COVID-19 infection: much more than a single pathway.|pdf=|usr=008}}
+
 
+
{{tp|p=32520031|t=2020. In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients.|pdf=|usr=008}}
+
 
+
 
+
 
+
{{tp|p=32380847|t=2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence.|pdf=|usr=008}}
+
{{tp|p=32516380|t=2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32515404|t=2020. Comprehensive overview of COVID-19 clinical trials.|pdf=|usr=008}}
+
{{tp|p=32515383|t=2020. Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.|pdf=|usr=008}}
+
 
+
 
+
 
+
{{tp|p=32395418|t=2020. An Update on Current Therapeutic Drugs Treating COVID-19.|pdf=|usr=008}}
+
{{tp|p=32391242|t=2020. A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.|pdf=|usr=008}}
+
{{tp|p=32467020|t=2020. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?|pdf=|usr=008}}
+
{{tp|p=32425691|t=2020. ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19.|pdf=|usr=008}}
+
{{tp|p=32385829|t=2020. COVID-19 and off label use of drugs: an ethical viewpoint.|pdf=|usr=008}}
+
{{tp|p=32449265|t=2020. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.|pdf=|usr=008}}
+
 
+
{{tp|p=32418299|t=2020. The COVID-19 chemoprophylactic conundrum: Are we limiting available resources?|pdf=|usr=008}}
+
{{tp|p=32406143|t=2020. Could patients taking isotretinoin therapy be immune against SARS-CoV-2?|pdf=|usr=008}}
+
 
+
{{tp|p=32390307|t=2020. Practical tips for using masks in the COVID-19 pandemic.|pdf=|usr=008}}
+
{{tp|p=32358890|t=2020. Cutaneous side-effects of the potential COVID-19 drugs.|pdf=|usr=008}}
+
 
+
 
+
 
+
{{tp|p=32428864|t=2020. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32514859|t=2020. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32451923|t=2020. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.|pdf=|usr=008}}
+
{{tp|p=32523611|t=2020. A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic.|pdf=|usr=008}}
+
{{tp|p=32499832|t=2020. Pharmacological treatment of COVID-19: lights and shadows.|pdf=|usr=008}}
+
{{tp|p=32520599|t=2020. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era.|pdf=|usr=008}}
+
 
+
{{tp|p=32469436|t=2020. Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.|pdf=|usr=008}}
+
{{tp|p=32378805|t=2020. COVID-19 and toxicity from potential treatments: Panacea or poison.|pdf=|usr=008}}
+
{{tp|p=32475694|t=2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.|pdf=|usr=008}}
+
{{tp|p=32482569|t=2020. Nutricion Clinica en tiempos de COVID-19.|pdf=|usr=008}}
+
{{tp|p=32495654|t=2020. Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.|pdf=|usr=008}}
+
{{tp|p=32379302|t=2020. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.|pdf=|usr=008}}
+
 
+
{{tp|p=32518390|t=2020. Editorial: Nutrition and COVID-19.|pdf=|usr=008}}
+
{{tp|p=32433599|t=2020. Nutritional management of COVID-19 patients in a rehabilitation unit.|pdf=|usr=008}}
+
{{tp|p=32404899|t=2020. Clinical significance of nutritional risk screening for older adult patients with COVID-19.|pdf=|usr=008}}
+
 
+
 
+
 
+
{{tp|p=32414641|t=2020. The quality of the reported sample size calculation in clinical trials on COVID-19 patients indexed in PubMed.|pdf=|usr=008}}
+
 
+
{{tp|p=32430428|t=2020. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.|pdf=|usr=008}}
+
{{tp|p=32398309|t=2020. Could the smoking gun in the fight against Covid-19 be the (rh) ACE2?|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32398976|t=2020. siRNA could be a potential therapy for COVID-19.|pdf=|usr=008}}
+
{{tp|p=32518634|t=2020. Lithium and coronaviral infections. A scoping review.|pdf=|usr=008}}
+
{{tp|p=32518636|t=2020. A snapshot of the ongoing clinical research on COVID-19.|pdf=|usr=008}}
+
{{tp|p=32395702|t=2020. The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?|pdf=|usr=008}}
+
 
+
{{tp|p=32426374|t=2020. Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy.|pdf=|usr=008}}
+
 
+
{{tp|p=32425923|t=2020. Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?|pdf=|usr=008}}
+
{{tp|p=32390971|t=2020. The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.|pdf=|usr=008}}
+
{{tp|p=32468851|t=2020. Facing the SARS-CoV-2 outbreak in the immunotherapy era.|pdf=|usr=008}}
+
{{tp|p=32406749|t=2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.|pdf=|usr=008}}
+
{{tp|p=32406253|t=2020. Bacillus Calmette Guerin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?|pdf=|usr=008}}
+
{{tp|p=32523109|t=2020. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2.|pdf=|usr=008}}
+
 
+
 
+
 
+
{{tp|p=32501513|t=2020. How to Rapidly Determine First-in-Children Dosing for COVID-19 Therapeutics.|pdf=|usr=008}}
+
{{tp|p=32433861|t=2020. How to Discover Antiviral Drugs Quickly.|pdf=|usr=008}}
+
{{tp|p=32515974|t=2020. Spiky Nanostructures with Geometry-matching Topography for Virus Inhibition.|pdf=|usr=008}}
+
 
+
{{tp|p=32514101|t=2020. First antibody against COVID-19 spike protein enters phase I.|pdf=|usr=008}}
+
 
+
{{tp|p=32529963|t=2020. Can lactoferrin boost human immunity against COVID-19?|pdf=|usr=008}}
+
{{tp|p=32535509|t=2020. COVID-19, interferons, and depression: A commentary.|pdf=|usr=008}}
+
{{tp|p=32409452|t=2020. Pandemic could add noise to clinical trial data.|pdf=|usr=008}}
+
 
+
{{tp|p=32527823|t=2020. Aggregating data from COVID-19 trials.|pdf=|usr=008}}
+
{{tp|p=32527819|t=2020. Can existing live vaccines prevent COVID-19?|pdf=|usr=008}}
+
 
+
{{tp|p=32520641|t=2020. Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al.|pdf=|usr=008}}
+
{{tp|p=32520639|t=2020. Response to Kim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19".|pdf=|usr=008}}
+
 
+
 
+
 
+
 
+
{{tp|p=32470338|t=2020. MORTALITY FROM COVID-19 INCREASES WITH UNSATURATED FAT, AND MAY BE REDUCED BY EARLY CALCIUM AND ALBUMIN SUPPLEMENTATION.|pdf=|usr=008}}
+
{{tp|p=32446698|t=2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.|pdf=|usr=008}}
+
{{tp|p=32427166|t=2020. Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19.|pdf=|usr=008}}
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
===007===
+
 
+
 
+
 
+
{{tp|p=32496248|t=2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.|pdf=|usr=007}}
+
{{tp|p=32496246|t=2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32476308|t=2020. Empirical Treatment and Prevention of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32466136|t=2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.|pdf=|usr=007}}
+
 
+
{{tp|p=32486229|t=2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.|pdf=|usr=007}}
+
{{tp|p=32481690|t=2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.|pdf=|usr=007}}
+
{{tp|p=32471278|t=2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.|pdf=|usr=007}}
+
{{tp|p=32471272|t=2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32443911|t=2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32429572|t=2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.|pdf=|usr=007}}
+
{{tp|p=32429099|t=2020. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32408699|t=2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.|pdf=|usr=007}}
+
{{tp|p=32392184|t=2020. Clinical trials for COVID-19 should include sex as a variable.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32457038|t=2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.|pdf=|usr=007}}
+
 
+
{{tp|p=32423974|t=2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32475104|t=2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.|pdf=|usr=007}}
+
{{tp|p=32293020|t=2020. Palliativ farmakologisk behandling vid svar covid-19.|pdf=|usr=007}}
+
{{tp|p=32444382|t=2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.|pdf=|usr=007}}
+
{{tp|p=32442946|t=2020. inverted question markBCG versus COVID-19?|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32162896|t=2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32455942|t=2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.|pdf=|usr=007}}
+
 
+
{{tp|p=32408547|t=2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).|pdf=|usr=007}}
+
{{tp|p=32486364|t=2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32486488|t=2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32423024|t=2020. The Rationale for Potential Pharmacotherapy of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32434254|t=2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32505040|t=2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32381590|t=2020. Ethics of controlled human infection to address COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32472939|t=2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.|pdf=|usr=007}}
+
 
+
{{tp|p=32395792|t=2020. COVID-19: Main therapeutic options.|pdf=|usr=007}}
+
{{tp|p=32507409|t=2020. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32486283|t=2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.|pdf=|usr=007}}
+
{{tp|p=32397643|t=2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.|pdf=|usr=007}}
+
 
+
{{tp|p=32485102|t=2020. Current Perspective of Antiviral Strategies against COVID-19.|pdf=|usr=007}}
+
{{tp|p=32369098|t=2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).|pdf=|usr=007}}
+
{{tp|p=32398377|t=2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32462848|t=2020. Interleukine-1 et blocage du COVID-19.|pdf=|usr=007}}
+
{{tp|p=32495979|t=2020. Emergence of novel coronavirus and progress toward treatment and vaccine.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32500793|t=2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32433189|t=2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.|pdf=|usr=007}}
+
 
+
{{tp|p=32473596|t=2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
{{tp|p=32391659|t=2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32057209|t=2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia].|pdf=|usr=007}}
+
{{tp|p=32397700|t=2020. [Analysis of application of herd immunity as a control strategy for COVID-19].|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32473600|t=2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.|pdf=|usr=007}}
+
{{tp|p=32491981|t=2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.|pdf=|usr=007}}
+
{{tp|p=32487283|t=2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.|pdf=|usr=007}}
+
{{tp|p=32490731|t=2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.|pdf=|usr=007}}
+
 
+
{{tp|p=32403995|t=2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.|pdf=|usr=007}}
+
{{tp|p=32499303|t=2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.|pdf=|usr=007}}
+
{{tp|p=32496239|t=2020. Potential pharmacological agents for COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32496237|t=2020. AYUSH for COVID-19: Science or Superstition?|pdf=|usr=007}}
+
{{tp|p=32454489|t=2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.|pdf=|usr=007}}
+
{{tp|p=32392562|t=2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32510105|t=2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
{{tp|p=32505909|t=2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.|pdf=|usr=007}}
+
 
+
{{tp|p=32492560|t=2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?|pdf=|usr=007}}
+
{{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=007}}
+
 
+
{{tp|p=32454510|t=2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.|pdf=|usr=007}}
+
 
+
{{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32442323|t=2020. Curcumin as a potential treatment for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32430996|t=2020. Potential effects of curcumin in the treatment of COVID-19 infection.|pdf=|usr=007}}
+
 
+
{{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32492211|t=2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.|pdf=|usr=007}}
+
 
+
{{tp|p=32492205|t=2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.|pdf=|usr=007}}
+
 
+
{{tp|p=32421836|t=2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.|pdf=|usr=007}}
+
 
+
{{tp|p=32427774|t=2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.|pdf=|usr=007}}
+
{{tp|p=32427277|t=2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.|pdf=|usr=007}}
+
{{tp|p=32495940|t=2020. Probiotics and COVID-19: is there any link?|pdf=|usr=007}}
+
{{tp|p=32504751|t=2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.|pdf=|usr=007}}
+
{{tp|p=32505910|t=2020. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1beta/neutrophil extracellular traps feedback loop.|pdf=|usr=007}}
+
{{tp|p=32502901|t=2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.|pdf=|usr=007}}
+
 
+
{{tp|p=32505070|t=2020. Nebulized Lidocaine in COVID-19, An Hypothesis.|pdf=|usr=007}}
+
 
+
{{tp|p=32369285|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369284|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369283|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369282|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369281|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32438383|t=2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.|pdf=|usr=007}}
+
{{tp|p=32325475|t=2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.|pdf=|usr=007}}
+
 
+
{{tp|p=32393915|t=2020. Biggest COVID-19 trial tests repurposed drugs first.|pdf=|usr=007}}
+
{{tp|p=32417850|t=2020. Drug researchers pursue new lines of attack against COVID-19.|pdf=|usr=007}}
+
{{tp|p=32415300|t=2020. Biotech companies prepare for COVID-19 downturn.|pdf=|usr=007}}
+
{{tp|p=32415251|t=2020. 15 drugs being tested to treat COVID-19 and how they would work.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32422645|t=2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.|pdf=|usr=007}}
+
{{tp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.|pdf=|usr=007}}
+
{{tp|p=32415276|t=2020. The sprint to solve coronavirus protein structures - and disarm them with drugs.|pdf=|usr=007}}
+
{{tp|p=32409766|t=2020. Dozens of coronavirus drugs are in development - what happens next?|pdf=|usr=007}}
+
{{tp|p=32405023|t=2020. Coronavirus drugs trials must get bigger and more collaborative.|pdf=|usr=007}}
+
 
+
{{tp|p=32512579|t=2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.|pdf=|usr=007}}
+
{{tp|p=32504019|t=2020. The coronavirus outbreak could make it quicker and easier to trial drugs.|pdf=|usr=007}}
+
{{tp|p=32424192|t=2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32324361|t=2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]|pdf=|usr=007}}
+
 
+
{{tp|p=32398330|t=2020. A Call for Pediatric COVID-19 Clinical Trials.|pdf=|usr=007}}
+
{{tp|p=32423342|t=2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?|pdf=|usr=007}}
+
{{tp|p=32393419|t=2020. Recent advances of therapeutic targets and potential drugs of COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32472655|t=2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.|pdf=|usr=007}}
+
{{tp|p=32501634|t=2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?|pdf=|usr=007}}
+
{{tp|p=32488956|t=2020. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32439730|t=2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?|pdf=|usr=007}}
+
 
+
{{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=007}}
+
 
+
{{tp|p=32385052|t=2020. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32381697|t=2020. The race is on for antibodies that stop the new coronavirus.|pdf=|usr=007}}
+
{{tp|p=32381692|t=2020. Combination prevention for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32461212|t=2020. Reducing transmission of SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32385101|t=2020. Rapid repurposing of drugs for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32327575|t=2020. NIH organizes hunt for drugs.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32409433|t=2020. Antivirals for COVID-19.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32420637|t=2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.|pdf=|usr=007}}
+
{{tp|p=32294756|t=2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.|pdf=|usr=007}}
+
 
+
{{tp|p=32438473|t=2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.|pdf=|usr=007}}
+
 
+
{{tp|p=32512271|t=2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32448098|t=2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.|pdf=|usr=007}}
+
 
+
{{tp|p=32448085|t=2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.|pdf=|usr=007}}
+
 
+
{{tp|p=32431217|t=2020. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32469418|t=2020. Evaluation of potential therapeutic options for COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32441805|t=2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.|pdf=|usr=007}}
+
{{tp|p=32437001|t=2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".|pdf=|usr=007}}
+
 
+
{{tp|p=32472779|t=2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?|pdf=|usr=007}}
+
{{tp|p=32508069|t=2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.|pdf=|usr=007}}
+
{{tp|p=32470199|t=2020. Metformin use amid coronavirus disease 2019 pandemic.|pdf=|usr=007}}
+
 
+
{{tp|p=32458502|t=2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.|pdf=|usr=007}}
+
{{tp|p=32458475|t=2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.|pdf=|usr=007}}
+
 
+
{{tp|p=32458425|t=2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32437019|t=2020. Baricitinib: A chance to treat COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32463459|t=2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.|pdf=|usr=007}}
+
 
+
{{tp|p=32428941|t=2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32498081|t=2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32449669|t=2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.|pdf=|usr=007}}
+
 
+
{{tp|p=32495917|t=2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
{{tp|p=32427004|t=2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?|pdf=|usr=007}}
+
{{tp|p=32452701|t=2020. An up-to-date overview of computational polypharmacology in modern drug discovery.|pdf=|usr=007}}
+
 
+
{{tp|p=32447996|t=2020. Treatments in the COVID-19 pandemic: an update on clinical trials.|pdf=|usr=007}}
+
{{tp|p=32475183|t=2020. Does lopinavir measure up in the treatment of COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32282262|t=2020. Treatment considerations for coronavirus (COVID-19).|pdf=|usr=007}}
+
{{tp|p=32469280|t=2020. COVID-19: Gene Transfer to the Rescue?|pdf=|usr=007}}
+
{{tp|p=32423245|t=2020. The Impact of the COVID-19 Pandemic on the Biotech Industry.|pdf=|usr=007}}
+
{{tp|p=32212981|t=2020. A Message to Our Community in the Midst of the COVID-19 Pandemic.|pdf=|usr=007}}
+
{{tp|p=32501133|t=2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?|pdf=|usr=007}}
+
{{tp|p=32503817|t=2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.|pdf=|usr=007}}
+
{{tp|p=32503816|t=2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.|pdf=|usr=007}}
+
 
+
{{tp|p=32503814|t=2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32449676|t=2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.|pdf=|usr=007}}
+
{{tp|p=32468014|t=2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32310670|t=2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32443151|t=2020. Lopinavir pharmacokinetics in COVID-19 patients.|pdf=|usr=007}}
+
{{tp|p=32462858|t=2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.|pdf=|usr=007}}
+
{{tp|p=32469279|t=2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.|pdf=|usr=007}}
+
 
+
{{tp|p=32462988|t=2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).|pdf=|usr=007}}
+
 
+
{{tp|p=32475223|t=2020. Antiviral effects of probiotic metabolites on COVID-19.|pdf=|usr=007}}
+
{{tp|p=32462970|t=2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32462996|t=2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.|pdf=|usr=007}}
+
 
+
{{tp|p=32476574|t=2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.|pdf=|usr=007}}
+
{{tp|p=32485061|t=2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.|pdf=|usr=007}}
+
 
+
{{tp|p=32433345|t=2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.|pdf=|usr=007}}
+
 
+
{{tp|p=32473011|t=2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.|pdf=|usr=007}}
+
{{tp|p=32504739|t=2020. Interleukin-17: A potential therapeutic target in COVID-19.|pdf=|usr=007}}
+
{{tp|p=32473010|t=2020. TPE-nAbs combination therapy for severe COVID-19.|pdf=|usr=007}}
+
{{tp|p=32220033|t=2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).|pdf=|usr=007}}
+
 
+
{{tp|p=32511912|t=2020. COVID-19: Drug targets and potential treatments.|pdf=|usr=007}}
+
{{tp|p=32469301|t=2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.|pdf=|usr=007}}
+
 
+
{{tp|p=32472703|t=2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.|pdf=|usr=007}}
+
{{tp|p=32427773|t=2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.|pdf=|usr=007}}
+
{{tp|p=32364561|t=2020. Randomized Clinical Trials and COVID-19: Managing Expectations.|pdf=|usr=007}}
+
{{tp|p=32463427|t=2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.|pdf=|usr=007}}
+
{{tp|p=32453363|t=2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32506195|t=2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32463794|t=2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32434272|t=2020. COVID-19Clinical trials: quality matters more than quantity.|pdf=|usr=007}}
+
 
+
{{tp|p=32464736|t=2020. A simulation training course for family medicine residents in China managing COVID-19.|pdf=|usr=007}}
+
{{tp|p=32505821|t=2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.|pdf=|usr=007}}
+
 
+
{{tp|p=32455629|t=2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.|pdf=|usr=007}}
+
 
+
{{tp|p=32398343|t=2020. Should azithromycin be used to treat COVID-19? A rapid review.|pdf=|usr=007}}
+
 
+
{{tp|p=32454500|t=2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.|pdf=|usr=007}}
+
{{tp|p=32453693|t=2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".|pdf=|usr=007}}
+
{{tp|p=32453692|t=2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32267762|t=2020. Research towards treating COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=007}}
+
{{tp|p=32442317|t=2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).|pdf=|usr=007}}
+
{{tp|p=32441783|t=2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).|pdf=|usr=007}}
+
{{tp|p=32441764|t=2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?|pdf=|usr=007}}
+
{{tp|p=32424836|t=2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.|pdf=|usr=007}}
+
{{tp|p=32449802|t=2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?|pdf=|usr=007}}
+
{{tp|p=32512007|t=2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.|pdf=|usr=007}}
+
{{tp|p=32445484|t=2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.|pdf=|usr=007}}
+
{{tp|p=32438446|t=2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.|pdf=|usr=007}}
+
{{tp|p=32508009|t=2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.|pdf=|usr=007}}
+
{{tp|p=32441462|t=2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32511867|t=2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.|pdf=|usr=007}}
+
{{tp|p=32418327|t=2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.|pdf=|usr=007}}
+
{{ttp|p=32449939|t=2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.|pdf=|usr=007}}
+
 
+
{{tp|p=32420947|t=2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).|pdf=|usr=007}}
+
{{tp|p=32420936|t=2020. Treatments for COVID-19: emerging drugs against the coronavirus.|pdf=|usr=007}}
+
{{tp|p=32425152|t=2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.|pdf=|usr=007}}
+
{{tp|p=32506621|t=2020. Drugs being investigated for children with COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32423954|t=2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.|pdf=|usr=007}}
+
 
+
{{tp|p=32493028|t=2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.|pdf=|usr=007}}
+
 
+
{{tp|p=32510142|t=2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32407491|t=2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.|pdf=|usr=007}}
+
 
+
{{tp|p=32403134|t=2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.|pdf=|usr=007}}
+
{{tp|p=32345591|t=2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.|pdf=|usr=007}}
+
{{tp|p=32303505|t=2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.|pdf=|usr=007}}
+
{{tp|p=32407551|t=2020. Interrogation of the safety and efficacy of home-use light-based devices.|pdf=|usr=007}}
+
 
+
{{tp|p=32480418|t=2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients.|pdf=|usr=007}}
+
 
+
{{tp|p=32498751|t=2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.|pdf=|usr=007}}
+
 
+
{{tp|p=32429705|t=2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.|pdf=|usr=007}}
+
{{tp|p=32412788|t=2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32503806|t=2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.|pdf=|usr=007}}
+
{{tp|p=32474583|t=2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.|pdf=|usr=007}}
+
{{tp|p=32459003|t=2020. A role for retinoids in the treatment of COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32459832|t=2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.|pdf=|usr=007}}
+
{{tp|p=32442287|t=2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32498131|t=2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.|pdf=|usr=007}}
+
 
+
{{tp|p=32350861|t=2020. COVID-19: A Defining Moment for Clinical Pharmacology?|pdf=|usr=007}}
+
{{tp|p=32442315|t=2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32212378|t=2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.|pdf=|usr=007}}
+
 
+
{{tp|p=32284037|t=2020. Perspective on the COVID-19 Coronavirus Outbreak.|pdf=|usr=007}}
+
{{tp|p=32174284|t=2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.|pdf=|usr=007}}
+
{{tp|p=32400323|t=2020. In vitro data of current therapies for SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32427000|t=2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
{{tp|p=32416679|t=2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.|pdf=|usr=007}}
+
{{tp|p=32394841|t=2020. COVID-19: An Update on Clinical Trials.|pdf=|usr=007}}
+
{{tp|p=32282303|t=2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.|pdf=|usr=007}}
+
{{tp|p=32475041|t=2020. Potential role of Anti-IL-17 in COVID-19 treatment.|pdf=|usr=007}}
+
{{tp|p=32473070|t=2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?|pdf=|usr=007}}
+
{{tp|p=32510814|t=2020. Omalizumab and COVID19 Treatment: Could It Help?|pdf=|usr=007}}
+
{{tp|p=32510734|t=2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.|pdf=|usr=007}}
+
{{tp|p=32510719|t=2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32500633|t=2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.|pdf=|usr=007}}
+
{{tp|p=32419517|t=2020. Emerging therapies for COVID-19 pneumonia.|pdf=|usr=007}}
+
{{tp|p=32429703|t=2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.|pdf=|usr=007}}
+
{{tp|p=32419524|t=2020. Old and re-purposed drugs for the treatment of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32223349|t=2020. How could artificial intelligence aid in the fight against coronavirus?|pdf=|usr=007}}
+
 
+
{{tp|p=32500928|t=2020. COVID-19 breakthroughs: separating fact from fiction.|pdf=|usr=007}}
+
  
  
{{tp|p=32419212|t=2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?|pdf=|usr=007}}
+
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
 +
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
 +
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
 +
Paper is (not yet in PubMed) :
  
{{tp|p=32401673|t=2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.|pdf=|usr=007}}
+
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
 +
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
 +
based on e.g.
  
{{tp|p=32428965|t=2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.|pdf=|usr=007}}
+
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
{{tp|p=32479158|t=2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?|pdf=|usr=007}}
+
{{tp|p=32464083|t=2020. P-selectin blockade in COVID-19-related ARDS.|pdf=|usr=007}}
+
{{tp|p=32437628|t=2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?|pdf=|usr=007}}
+
  
 +
=======================================================================================
  
{{tp|p=32446312|t=2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.|pdf=|usr=007}}
+
COVID19 is now a CURABLE disease !!!
{{tp|p=32503855|t=2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.|pdf=|usr=007}}
+
  
{{tp|p=32340978|t=2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.|pdf=|usr=007}}
+
=======================================================================================
-rest-
+
{{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
+
{{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency  and Similar Future Global Health Threats |pdf=|usr=}}
+
{{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
+
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
+
{{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
+
{{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
+
{{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
+
{{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
+
{{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
+
{{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}}
+
{{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}}
+
{{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}}
+
{{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}}
+
{{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}}
+
{{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}}
+
{{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}}
+

Aktuelle Version vom 21. September 2021, 06:15 Uhr

homepage
hottest actual papers
 P further streaming-in related content is here
 CHERRYPICKING STUDIES IS NOT SCIENCE
Reviews on covid drug development


PHA related options:


A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
=======================================================================================
COVID19 is now a CURABLE disease !!!
=======================================================================================

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis